Clinical Trial Update: Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients as Biomarkers for Efficacy of Sublingual Immunotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial investigating serum microRNAs 223 and 146a as biomarkers for efficacy of sublingual immunotherapy in allergic rhinitis; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Snippet

Sponsor: Zagazig University | Conditions: Effects of Immunotherapy | Phase 3 | Status: COMPLETED